Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating ...

The ETESIAN study is evaluating a single administration of subcutaneous briquilimab in patients with asthma. “Dosing of the first patient in our ETESIAN study in asthma is a significant ...

April 4, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), the leader in antisense therapeutics, and its partner, AstraZeneca, today announced positive data from the ETESIAN Phase ...

Etesian provides unique integration between customers’ needs and manufacturers’ capabilities. The collaboration offers TowerJazz’s customers the option of using Etesian as program and supply ...

April 10 - Tower Semiconductor Ltd. (NASDAQ: TSEM; TASE: TSEM), an independent specialty foundry, today announced teaming up with ETesiAN Semiconductor to provide local support for Tower's growing ...

Positive results from the ETESIAN Phase IIb trial showed AZD8233 (an investigational antisense oligonucleotide [ASO], also known as ION449) met the primary endpoint at 50 mg with 73% (95% confidence ...

Etesian Wealth Advisors Inc.’s holdings in Microsoft were worth $5,687,000 as of its most recent SEC filing. A number of other institutional investors and hedge funds have also made changes to ...

Results of the phase 2b ETESIAN trial of AZD8233 showed that the drug was effective, reducing low-density lipoprotein cholesterol (LDL-C) levels by 73% from baseline, when given as a once-monthly ...

CANADA, FRANCE: Elliptic Technologies has partnered with ETesiAN Semiconductor to further strengthen Elliptic’s support for highly integrated embedded security solutions in the mobile ...